NCT05180097 2026-02-02Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaCanadian Cancer Trials GroupPhase 2 Recruiting84 enrolled